Pharmaceutical intelligence for Sichuan Baili Pharmaceutical Co., Ltd. with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

ClinicalJuly 29, 2026

Phase II/III Trial of BL-B01D1 with Osimertinib in EGFR-mutant NSCLC Initiated

A Phase II/III trial has been initiated to evaluate BL-B01D1 combined with osimertinib in patients with resectable EGFR-mutant non-small cell lung cancer.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalJuly 29, 2026

Phase II/III Trial of BL-B01D1 with Osimertinib in EGFR-mutant NSCLC Initiated

A Phase II/III trial has been initiated to evaluate BL-B01D1 combined with osimertinib in patients with resectable EGFR-mutant non-small cell lung cancer.

Competitive activity

No signals indexed for this entity yet.

Assets

osimertinib →

Therapeutic areas

NSCLC →

Oncology →

Indications

NSCLC →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.